Aurora Cannabis Reports Mixed Q1 FY2027: International Growth Offsets Domestic Pressures
Event summary
- Aurora Cannabis reported $67.6M in net revenue for Q1 FY2027, down 9% YoY due to Canadian medical cannabis declines and consumer segment wind-down.
- International medical cannabis revenue grew 17% YoY to $43.3M, driven by German market demand.
- Adjusted EBITDA fell 68% YoY to $3.4M, impacted by lower gross margins from Canadian reimbursement program changes.
- Acquired Safari Flower Company in April 2026, adding EU-GMP certified cultivation capacity for international expansion.
The big picture
Aurora's strategic pivot toward international medical cannabis markets reflects broader industry trends of consolidation and geographic diversification. The company's ability to offset Canadian margin pressures through higher-margin European sales will be critical as it invests $3.5M over three years in EU-GMP capacity expansion. Success hinges on maintaining operational efficiency while navigating regulatory complexities across key markets.
What we're watching
- International Expansion
- Whether Aurora can sustain its 17% YoY international medical cannabis growth through strategic EU-GMP capacity investments.
- Regulatory Impact
- How Canadian federal reimbursement program changes will continue affecting domestic medical cannabis margins.
- Operational Efficiency
- The pace at which Safari Flower Company integration improves product availability and reduces third-party supplier reliance.
Related topics